Find out everything you need to know about deciding to make in-house or outsource your cell and gene therapy manufacturing process

Fill out the form below to watch the webinar.

As you are establishing your commercial strategy for cell and gene therapy manufacturing, evaluating whether to build in-house capabilities or leverage a CDMO comes to the forefront of the discussion. When it comes to making the decision, a wide range of factors must be taken into account, from current investment capability to meeting your company’s long-term goals while maintaining flexibility in a continuously changing climate.

Watch this webinar, Build vs. Buy Dilemma – Economics of Manufacturing Cell-based Therapies, where our Thermo Fisher Scientific expert will take you through everything you need to consider when setting up a commercial strategy for success.

You’ll learn about:

  • Key considerations related to the build vs. buy decision for cell therapy manufacturing
  • Flexible and sustainable design strategies and best practices
  • Contingency planning based on current market conditions and exit strategies